FOLD - Amicus Therapeutics Inc Qarzning balans kapitallashuviga nisbati

Amicus Therapeutics Inc (FOLD) grafik logotipi

John Crowley rahbarligida Amicus Therapeutics (FOLD) kamyob kasalliklar terapiyasi bo'yicha global ustunlikka intilmoqda. Pul birliklarida 1.62 qiymati bilan ifodalangan bozor tendentsiyasi Pompe kasalligi davolash uchun sug'urta to'lovlari bo'yicha uzoq davom etgan bahslar bilan bog'liq. Shu bilan birga, biznes dori vositalarining ulkan marjalariga tayanadi, bunda minimal sintez xarajatlari eksklyuziv bemorlar parvarishi uchun besh xonali hisob-fakturalar bilan qoplanadi.

FOLD (Amicus Corp) Qarzning balans qiymatiga nisbati tarixi 04.07.2022dan 09.05.2026gacha

Amicus Therapeutics Inc (FOLD) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Amicus Therapeutics|FOLD - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Amicus Corp|FOLD - Qarz va naqd pullar hisobga olingan qiymat
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Amicus Therapeutics|FOLD - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati amicusrx.com|FOLD - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati Amicus Therapeutics|FOLD - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Amicus Pharma|FOLD - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Amicus Corp
Kompaniyaning fundamental tahlili:Amicus Therapeutics - FOLD
Amicus Pharma asosiy tovari

Ushbu ko'rsatkich majburiyatlar tuzilmasining barqarorligi va bankrotlik xatarlarini baholash uchun umumiy majburiyatlarni kapitalga nisbatan solishtirish orqali moliyaviy leveraj darajasini o'lchaydi. Amicus Therapeutics (FOLD) kompaniyasining umumiy qarzning kapitalizatsiyaga nisbati ko'rsatkichini tahlil qilish, kompaniya yuqori marjali ishlab chiqarishni kengaytirish bosqichiga kirishdan oldin, qimmat turadigan kamyob kasalliklar dori vositalarini ishlab chiqishni qanchalik samarali moliyalashtirayotganini ochib beradi.

Amicus Therapeutics (FOLD) raqobatchilari

Balans kapitallashuviga qarzlar ASND (Ascendis Pharma A/S)|madrigalpharma.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Corcept Therapeutics Incorporated (CORT)|RYTM: Qarzning sof aktivlarga nisbati|AKRO (Akero Therapeutics Inc) - Qarzning balans kapitallashuviga nisbati|Metsera Therapeutics (MTSR) - Qarzning balans qiymatiga nisbati|MLTX (MoonLake Immunotherapeutics) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati SLNO (Soleno Therapeutics Inc)|89bio Corp - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati Agios Corp AGIO|GPCR (Structure Therapeutics) - Balans kapitallashuviga qarzlar|mimedx.com (MDXG) - Balans qiymatiga qarzlar|RZLT - Qarzning balans qiymatiga nisbati|Lexicon Pharmaceuticals Inc (LXRX) - Qarzning balans kapitaliga nisbati|MBX (MBX Bio) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar Altimmune Pharma|Balans kapitallashuviga qarzlar Aardvark Therapeutics Inc (AARD)|Qarzning balans kapitallashuviga nisbati SGMT (sagimet.com)|BIOA: Qarzning balans kapitallashuviga nisbati|Biomea Fusion Inc - Balans qiymatiga qarzlar|QNCX - Qarzning balans kapitallashuviga nisbati|GUTS - Qarzning balans kapitallashuviga nisbati|vtvtherapeutics.com - Balans kapitallashuviga qarzlar|ATPC (Agape ATP) - Sof aktivlarga qarzlar|PLUR: Qarzning balans kapitallashuviga nisbati|Sof aktivlarga qarzlar SYBX|Qarzning balans kapitallashuviga nisbati LPCN (Lipocine Corp)|Qarzning balans qiymatiga nisbati matinasbiopharma.com (MTNB)|Balans kapitallashuviga qarzlar SPRB (Spruce Biosciences, Inc.)|galecto.com - Balans kapitallashuviga qarzlar|CTCX: Qarzning balans kapitallashuviga nisbati|LUMO - Qarzning balans qiymatiga nisbati|Organovo Holdings Inc - Balans kapitallashuviga qarzlar|Radius Pharmaceuticals (RDUS) - Sof aktivlarga qarzlar